series-b
Stage
About
Sudo Biosciences is a clinical-stage neuro-immunology biotechnology company developing small-molecule TYK2 inhibitors for neurological and immune-mediated inflammatory diseases such as multiple sclerosis and psoriasis. The company advances brain-penetrant and allosteric TYK2 programs through preclinical and early clinical development.
Explore Sudo Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.